Valproate leads to higher response rate at 3 weeks (primary efficacy outcome) compared with placebo (high certainty).
Valproate showed no clear difference in response rate at 3 weeks (primary efficacy outcome) compared with lithium (moderate certainty).
It is very uncertain whether valproate changes response rate at 8 weeks (primary efficacy outcome) compared with lithium (very low certainty).
Valproate may leads to lower response rate at 8 weeks (primary efficacy outcome) compared with risperidone (low certainty).
It is very uncertain whether valproate changes response rate at 4 weeks (primary efficacy outcome) compared with placebo (very low certainty).
Valproate showed no clear difference in response rate at endpoint at 3 weeks (primary efficacy outcome) compared with olanzapine (low certainty).